Dew, et al, it's apparent the company is preparing for accelerated approval. Will they achieve it for both naive and non-repsonder indications.
Vertex expects to make a significant investment in the commercial supply for telaprevir (VX- 950) in 2007, subject to continued progress of the drug candidate.
Hmmmm. Guess we know another reason for the recent placement, gearing up for launch. I wonder if they'll raise more cash in the next six months.
Market Data 
Markets 
AI
